S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$144.92
+1.51 (+1.05%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$143.91
$145.33
50-Day Range
$133.98
$157.77
52-Week Range
$125.36
$169.98
Volume
423,315 shs
Average Volume
530,540 shs
Market Capitalization
$9.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$204.27

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
41.0% Upside
$204.27 Price Target
Short Interest
Healthy
3.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.93mentions of Jazz Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.06 M Sold Last Quarter
Proj. Earnings Growth
15.33%
From $14.68 to $16.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

45th out of 1,009 stocks

Pharmaceutical Preparations Industry

11th out of 494 stocks


JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

Zymeworks Offers Hope for More than Just Long-Term Investors (JAZZ)
Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Asparaginase Market Growth and Forecast till 2031
Clozapine Market Share and Forecast till 2028
RBC Capital Keeps Their Buy Rating on Nuvation Bio (NUVB)
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2021
Today
3/30/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$204.27
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+41.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-224,060,000.00
Pretax Margin
-10.19%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$22.33 per share
Book Value
$49.01 per share

Miscellaneous

Free Float
60,544,000
Market Cap
$9.18 billion
Optionable
Optionable
Beta
0.73

Social Links


Key Executives

  • Bruce C. CozaddBruce C. Cozadd
    Chairman & Chief Executive Officer
  • Daniel N. Swisher
    President
  • Renée D. Galá
    Chief Financial Officer & Executive Vice President
  • Robert Iannone
    Executive Vice President-Research & Development
  • Finbar LarkinFinbar Larkin
    Senior Vice President-Technical Operations













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

8 Wall Street analysts have issued twelve-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they expect the company's share price to reach $204.27 in the next year. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 on January 1st, 2023. Since then, JAZZ shares have decreased by 9.0% and is now trading at $144.92.
View the best growth stocks for 2023 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to the consensus estimate of $829.98 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 24.04% and a negative net margin of 6.12%. During the same period in the prior year, the firm earned $3.86 earnings per share.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of $16.90-$17.85 for the period, compared to the consensus estimate of $18.10. The company issued revenue guidance of $3.675-$3.875 billion, compared to the consensus revenue estimate of $3.76 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (4.53%), LSV Asset Management (3.26%), Renaissance Technologies LLC (2.05%), Franklin Resources Inc. (2.03%), Polaris Capital Management LLC (1.99%) and Geode Capital Management LLC (1.49%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $144.92.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.18 billion and generates $3.66 billion in revenue each year. The specialty pharmaceutical company earns $-224,060,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 2,800 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 3/31/2023 by MarketBeat.com Staff